Objective To assess the suitability of Australian community pharmacies as cardiovascular disease risk profile screening centres and evaluate whether community pharmacists can play an important role in detecting, educating and referring screened individuals at high risk of cardiovascular disease. Setting 14 Australian community pharmacies. Method Opportunistic cardiovascular disease risk profiling for members of the public aged greater than 30 years with no existing cardiovascular diseases was performed. All major cardiovascular risk factors were measured. Exercise habits, existing conditions and therapy, and family history were also assessed. The results were used to calculate each subject’s 10-year risk of developing cardiovascular events, based on Framingham Risk Equations (New Zealand tables). Each subject’s knowledge of cardiovascular risk factors was assessed using a multiple-choice questionnaire. Written educational materials and verbal counselling were provided. Referral to a doctor for further assessment was recommended as appropriate. The screened individuals were followed up via mailed out questionnaire. A random sample of individuals at elevated risk was phoned to assess for outcomes of the screening and referral process. Main outcome measures Risk of developing cardiovascular disease and knowledge of cardiovascular risk factors. Results A total of 655 individuals (71.4% female) were screened for cardiovascular disease risk factors. Ages ranged from 30 to 90 years (median: 54 years) and 14.2% were smokers. Of the individuals screened, 28.1% had a 10-year risk of developing cardiovascular disease greater than 15%, including 6.9% who had a 10-year risk above 30%. The median calculated 10-year risk of developing cardiovascular disease was 9.5%. Approximately one-third of the individuals had elevated blood pressure, and almost two-thirds were either overweight or obese. The mean total serum cholesterol was 5.31 mmol/l, with 40% of individuals having a level above 5.5 mmol/l and 20% having a high-density lipoprotein cholesterol level below 1.0 mmol/l. There was a statistically significant improvement in the knowledge of cardiovascular disease risk factors at follow-up. Almost half of the contacted high-risk subjects reported lifestyle changes or started drug therapy following re-testing by their general practitioner. Conclusion A pharmacy-based cardiovascular disease risk profile screening and education program has the potential to identify and refer many undiagnosed individuals at high risk of cardiovascular events, and help contain the burden of heart disease.
Australia Cardiovascular disease Detection Pharmacy Risk Screening
This is a preview of subscription content, log in to check access.
We thank Madeleine Ball, Roger Rumble, Mark Naunton and Sue Owen for their contributions to this work.
This research was funded by the Australian Government Department of Health and Ageing through the Third Community Pharmacy Agreement Research and Development Program.
Conflicts of interest statement
None to declare
World Health Organization. Neglected global epidemics: three growing threats. The World Health Report—shaping the future. Geneva: World Health Organization; 2003. p. 83–102.Google Scholar
Australian Institute of Health and Welfare. Australia’s health 2006. AIHW cat. no. AUS 73. Canberra: AIHW. 2006.Google Scholar
National Heart Foundation of Australia. The shifting burden of cardiovascular disease. Report prepared by Access Economics 2005. Canberra: National Heart Foundation of Australia.Google Scholar
Prepared by: British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society. The Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl 5):v1–52. doi:10.1136/hrt.2005.079988.
Joyce AW, Sunderland VB, Burrows S, et al. Community pharmacy’s role in promotion of healthy behaviours. J Pharm Pract Res. 2007;37:42–4.Google Scholar
Phillips S, Wyndham L, Shaw J, Walker S. How accurately does the Reflotron dry-chemistry system measure plasma total cholesterol levels when used as a community-screening device? Med J Aust. 1988;149:122–5.PubMedGoogle Scholar
Kinlay S. Comparison of Reflotron and laboratory cholesterol measurements. Med J Aust. 1988;149:126–9.PubMedGoogle Scholar
Ball MJ, Robertson IK, Woods M. Reflotron cholesterol measurement in general practice—accuracy and detection of errors. Ann Clin Biochem. 1994;31:556–60.PubMedGoogle Scholar
Gregory LC, Duh SH, Christenson RH. Eight compact analysis systems evaluated for measuring total cholesterol. Clin Chem. 1994;40:579–85.PubMedGoogle Scholar
Thue G, Sandberg S, Bullock DG. Comparison of the use of a dry chemistry analyser in primary care in Norway and the United Kingdom. Br J Gen Pract. 1993;43:10–4.PubMedGoogle Scholar
Warnick GR, Boerma GJ, Assmann G, et al. Multicenter evaluation of Reflotron direct dry-chemistry assay of high-density lipoprotein cholesterol in venous and fingerstick specimens. Clin Chem. 1993;39:271–7.PubMedGoogle Scholar
New Zealand Guidelines Group. The assessment and management of cardiovascular risk, 2003. Available at: http://www.nzgg.org.nz. Accessed June 2007.
Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med. 2002;162:1149–55. doi:10.1001/archinte.162.10.1149.CrossRefPubMedGoogle Scholar
Mangum SA, Kraenow KR, Narducci WA. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm Assoc. 2003;43(1):50–5. doi:10.1331/10865800360467042.CrossRefGoogle Scholar
Snella KA, Canales AE, Irons BK, et al. Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals. J Am Pharm Assoc. 2006 May–Jun;46(3):370–7. doi:10.1331/154434506777069598.